Publications by authors named "Kenneth Ataga"

Claim this Profile
E
Enhanced PIEZO1 function contributes to the pathogenesis of sickle cell disease.
Luis O Romero, Manisha Bade, Laila Elsherif, Jada D Williams, Xiangmei Kong, Kenneth I Ataga

Proc Natl Acad Sci U S A· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.
Rima S Zahr, Guolian Kang, Xu Zhang, Sara R Rashkin, Csaba P Kovesdy, Kenneth I Ataga

Am J Hematol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NO (nitric oxide) to priapism with hydroxyurea and tadalafil.
Kenneth I Ataga

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Kenneth I Ataga

Lancet Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced PIEZO1 Function Contributes to the Pathogenesis of Sickle Cell Disease.
Luis O Romero, Manisha Bade, Laila Elsherif, Jada D Williams, Xiangmei Kong, Kenneth I Ataga

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
Modupe Idowu, Lucas Otieno, Bogdan Dumitriu, Clarisse L C Lobo, Swee Lay Thein, Kenneth I Ataga

Lancet Haematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of biomarkers of endothelial function, coagulation activation and kidney injury with persistent albuminuria in sickle cell anaemia.
Laila Elsherif, Yihan Tang, Kammie L Patillo, David Wichlan, Ugochi O Ogu, Kenneth I Ataga

Br J Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble urokinase plasminogen activator receptor is associated with kidney disease and its progression in sickle cell anemia.
Rima S Zahr, Sara R Rashkin, Maria Armila Ruiz, Laila Elsherif, Guohui Ren, Kenneth I Ataga

Haematologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent albuminuria and chronic kidney disease in adults with sickle cell anaemia: Results from a multicenter natural history study.
Laura Y Zhou, Vimal K Derebail, Payal C Desai, Laila Elsherif, Kammie L Patillo, Kenneth I Ataga

Br J Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concerns With Statistical Analysis of 2016 CDC Opioid Guideline and Sickle Cell Outcomes-Reply.
Hyeun Ah Kang, Yahan Zhang, Kenneth I Ataga

JAMA Intern Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel.
Julie Kanter, Kenneth I Ataga, Neha Bhasin, Stephanie Guarino, Abdullah Kutlar

Ann Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid Prescribing and Outcomes in Patients With Sickle Cell Disease Post-2016 CDC Guideline.
Hyeun Ah Kang, Bofei Wang, Jamie C Barner, Kenneth I Ataga, Robert C Mignacca

JAMA Intern Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
Mark T Gladwin, Victor R Gordeuk, Payal C Desai, Caterina Minniti, Enrico M Novelli, Kenneth I Ataga

Lancet Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydroxyurea at escalated dose versus fixed low-dose hydroxyurea in adults with sickle cell disease.
Ugochi O Ogu, Ayesha Mukhopadhyay, Kruti Patel, Marquita N Nelson, KayLee S Strahan, Kenneth I Ataga

Eur J Haematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney failure outcomes in children and young adults with sickle cell disease in the United States Renal Data System.
Rima S Zahr, Kenneth I Ataga, Jeffrey D Lebensburger, Jeffrey C Winer

Pediatr Nephrol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Predicts Acute Kidney Injury in Hospitalized Patients with Sickle Cell Disease.
Rima S Zahr, Akram Mohammed, Surabhi Naik, Daniel Faradji, Kenneth I Ataga

Am J Nephrol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
Ming Chen, Jane S Hankins, Min Zhang, Kenneth I Ataga

Am J Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel.
Deva Sharma, Ilknur Kozanoğlu, Kenneth I Ataga, Alexandra Benachi, Selim Büyükkurt

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The challenge of clinical end points in sickle cell disease.
Kenneth I Ataga

Blood· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using disease-modifying therapies in sickle cell disease.
Parul Rai, Kenneth I Ataga

Hematology Am Soc Hematol Educ Program· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-related differences in risks and outcomes of 30-day readmission in adults with sickle cell disease.
Ming Chen, Kenneth I Ataga, Jane S Hankins, Min Zhang, Justin D Gatwood

Ann Hematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Kwaku Marfo, Yvonne Dei-Adomakoh, Catherine Segbefia, Duah Dwomoh, Adeline Edgal, Kenneth I Ataga

BMC Health Serv Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary angiotensinogen is associated with albuminuria in adults with sickle cell anaemia.
Laila Elsherif, Praghalathan Kanthakumar, Jeremiah Afolabi, Ashley F Stratton, Ugochi Ogu, Kenneth I Ataga

Br J Haematol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences in progression of kidney disease in sickle cell disease.
Kenneth I Ataga, Qingning Zhou, Santosh L Saraf, Jane S Hankins, Emily J Ciccone

Haematologica· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End Stage Kidney Disease Outcomes in Children and Young Adults with Sickle Cell Disease in the United States Renal Data System.
Rima S Zahr, Kenneth I Ataga, Jeffrey D Lebensburger, Jeffrey C Winer

Res Sq· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis